跳至主要内容
临床试验/NCT07320768
NCT07320768进行中(未招募)不适用

The Efficacy and Safety of Renal Denervation Combined With Pulsed Field Ablation in Preventing Recurrence of Atrial Arrhythmia in Patients With Persistent Atrial Fibrillation: An OFF-MED Trial

Shanghai Chest Hospital1 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2026年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
86
试验地点
1
主要终点
Freedom from Atrial Arrhythmia Recurrence

研究概览

简要总结

The goal of this clinical trial is to learn whether adding renal denervation (RDN) to pulsed-field ablation (PFA) reduces recurrence of atrial tachyarrhythmias in adults (≥18 years) with persistent atrial fibrillation undergoing first-time ablation while off antiarrhythmic drugs.

The main questions it aims to answer are:

  1. Does PFA+RDN, compared with PFA alone, reduce the proportion of participants with any AF/atrial flutter/atrial tachycardia ≥30 seconds at 12 month?
  2. Is PFA+RDN safe, as measured by procedure-related serious adverse events through 30 days?

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years.
  • Patients with persistent atrial fibrillation undergoing first-time catheter ablation (defined as any episode lasting ≥7 days).
  • Symptomatic atrial fibrillation refractory to or intolerant of at least one class I or III antiarrhythmic drug and scheduled for guideline-directed catheter ablation.
  • Able to understand the study purpose, voluntarily participate, and sign the written informed consent form.

排除标准

  • Presence of advanced structural heart disease.
  • Life expectancy < 12 months.
  • Blood pressure < 90/60 mmHg.
  • Pregnant or lactating women.
  • Anatomical abnormalities of the renal arteries unsuitable for treatment as determined by pre-procedural renal CTA.
  • History of renal artery intervention, impaired renal function with estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m² (calculated by the MDRD equation).
  • Secondary atrial fibrillation due to electrolyte imbalance, thyroid disorders, or other reversible or non-cardiac causes.
  • Contraindication to pulsed-field ablation (e.g., left atrial thrombus, prior atrial septal defect occluder implantation, or permanent metallic implant in the left atrium) or to anticoagulation therapy.
  • Known inability to obtain vascular access or contraindication to femoral venous puncture.
  • Heart failure with left ventricular ejection fraction < 30% documented by transthoracic echocardiography within 3 months before ablation.
  • Patients with current or anticipated need for pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT), or prior transseptal closure with occluder device for atrial septal defect or patent foramen ovale.

研究组 & 干预措施

pulsed-field ablation alone

Sham Comparator

干预措施: Pulsed-Field Ablation (PFA) (Procedure)

renal denervation combined with pulsed-field ablation

Experimental

干预措施: renal denervation (Procedure)

renal denervation combined with pulsed-field ablation

Experimental

干预措施: Pulsed-Field Ablation (PFA) (Procedure)

结局指标

主要结局

Freedom from Atrial Arrhythmia Recurrence

时间窗: within 12 Months After the Index Procedure

Absence of any documented atrial tachyarrhythmia - including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds - occurring

次要结局

  • Freedom from AF recurrence(within 3 months after the index procedure)
  • Atrial fibrillation burden(at 3 months)
  • Change in blood pressure(immediately, at 1 month, and at 3 months after procedure)
  • Major adverse cardiovascular events (MACE)(up to 12 months after ablation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wenzheng Han

Associate Chief Physician; Administrative Deputy Director, Department of Cardiology

Shanghai Chest Hospital

研究点 (1)

Loading locations...

相似试验